arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

PROTHENA CORP PUBLIC LTD CO

PRTA
$7.90 ▼ -0.50 (-5.95%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
21
Health
Poor
Bearish
auto_awesome

Analytical Summary

PROTHENA CORP PUBLIC LTD CO faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $425.2M
Dividend Yield —
Revenue Growth -92.8% ↘
Op. Margin None
ROIC -93.0% ↘
FCF / Share $-3.04 ↘
Trailing P/E —
Price / Book 1.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.68M
↓ -92.8% —
Net Income Profit after all expenses
$-244.09M
↓ -99.6% —
Operating Margin Operating profit as % of sales
-114.4%
↑ +45.3% —
FCF / Share Free cash flow per share
$-3.04
↓ -8.9% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
11
Cash Quality ↓
47

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 60 quarters